A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain

First proof to show that (−)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first β-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) substance and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), the tryptamine-d...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2017-08, Vol.182, p.57-64
Main Authors: Knoll, J., Baghy, K., Eckhardt, S., Ferdinandy, P., Garami, M., Harsing, L.G., Hauser, P., Mervai, Z., Pocza, T., Schaff, Z., Schuler, D., Miklya, I.
Format: Article
Language:English
Subjects:
(2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)
Amine oxidase (flavin-containing)
Animals
Antineoplastic Agents - pharmacology
Benzofuran
Benzofurans - administration & dosage
Benzofurans - pharmacology
Biotechnology
Brain
Brain - drug effects
Brain - metabolism
Cell Line, Tumor
Cisplatin
Cognitive enhancement
Cytotoxicity
Dose-Response Relationship, Drug
Enhancer substances
Enhancer-sensitive tumor-manifestation-suppressing (TMS) regulation
Etoposide
Fibromyxosarcoma
Fibrosarcoma - prevention & control
Humans
Longevity
Longevity - drug effects
Male
Markers
Medulloblastoma
Medulloblastoma - drug therapy
Monoamine Oxidase Inhibitors - administration & dosage
Monoamine Oxidase Inhibitors - pharmacology
Phenethylamine
Phenylethylamine
Rats
Rats, Wistar
Regulations
Selegiline
Selegiline - administration & dosage
Selegiline - pharmacology
Selegiline/(−)-deprenyl
Temozolomide
Tryptamine
Tumor cells
Vesicular monoamine transporter 2
Vincristine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:First proof to show that (−)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first β-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) substance and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), the tryptamine-derived presently known most potent, selective, synthetic enhancer substance, are specific markers of unknown enhancer-sensitive brain regulations. Longevity study disclosing the operation of tumor-manifestation-suppressing (TMS) regulation in rat brain. Immonohistochemical identification of a fibromyxosarcoma in rats. Experiments with human medulloblastoma cell lines. Analysis of the mechanism of action of enhancer substances. Whereas 20/40 saline-treated rats manifested a fibromyxosarcoma, in groups of rats treated with 0.001mg/kg DEP: 15/40 rats; with 0.1mg/kg DEP: 11/40 rats (P
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2017.06.010